


2025/9/25

Announcement Regarding Discovery of Therapeutic Effects of Umedaptanib Pegol in a Diabetic Retinopathy Model and New Patent Application for Use

TOKYO, September 25, 2025 - RIBOMIC, Inc. (TYO:4591), a clinical-stage pharmaceutical company specializing in aptamer therapeutics, has discovered promising therapeutic effects of umedaptanib pegol (anti-FGF2 aptamer) in a diabetic retinopathy model and have completed the patent application for its use in treating diabetic retinopathy.

Diabetic retinopathy is a well-known visual impairment that develops as a complication of diabetes, involving retinal vascular abnormalities and edema. In diabetic retinopathy, detachment of the pericytes (pericellular cells) surrounding retinal blood vessels is frequently observed. This detachment is known to cause disruption of the blood-retinal barrier, microvascular damage, and fundus hemorrhage. In this study, we employed a mouse model of diabetic retinopathy utilizing an anti-PDGFR β antibody. This model reproduces the pathology where detachment of pericytes surrounding retinal vascular endothelium causes disruption of the blood-retinal barrier and retinal hemorrhage. As shown in the figure, the group administered umedaptanib pegol exhibited a significant suppression in the occurrence of retinal hemorrhage. These results strongly suggest that umedaptanib pegol possesses a vascular stabilizing effect and can suppress the progression of diabetic retinopathy.



Diabetic retinopathy is one of the three major complications of diabetes and a leading cause of blindness in Japanese adults. Although anti-VEGF drugs are used to treat diabetic retinopathy, their response rate is limited, making the development of new treatments desirable. Umedaptanib pegol has demonstrated therapeutic efficacy and safety via intravitreal administration in our Phase 2 clinical trial for wet age-related macular degeneration (wet AMD) in the United States. This enables us to initiate a Phase 2 clinical trial of umedaptanib pegol via intravitreal injection for diabetic retinopathy. We believe this will contribute to expanding our clinical pipeline and enhancing corporate value.

ABOUT UMEDAPTANIB PEGOL

Umedaptanib pegol is a novel oligonucleotide-based aptamer formerly designated RBM-007,

with potent anti-FGF2 (fibroblast growth factor 2) activity. The drug has demonstrated clinical Proof-of-Concept (POC) in exudative age-related macular degeneration and achondroplasia.

ABOUT RIBOMIC

RIBOMIC is a clinical-stage biopharmaceutical company specializing in the discovery and development of aptamer therapeutics, a type of nucleic acid medicine with great potential for the development of next-generation drugs. The RiboART system, the company's core drug discovery platform, can be used to discover many types of aptamer drugs. RIBOMIC is dedicated to the discovery and development of drugs targeting the broad field of unmet medical needs, which includes eye disease, rare childhood disease of short stature, and many other diseases.

Please visit the RIBOMIC website for more information.

<https://www.ribomic.com/eng/>

Forward-Looking Statements This announcement contains forward-looking statements relating to current plans, estimates, strategies, belief and the future performance of Company. These statements are based on Company's current expectations in light of the information and assumptions currently available so that Company does not promise the realization and these expectations may differ materially from those discussed in the forward-looking statements. These factors include, but not limited to, i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, ii) currency exchange rate fluctuations, iii) claims and concerns on the product safety and efficacy, iv) completion and News Release discontinuation of clinical trials, v) infringement of Company's intellectual property rights by third parties.

Information on pharmaceutical products (including products currently in development), which is included in this press release is not intended to constitute an advertisement or medical advice.

"RIBOMIC," "RiboART system" and the RIBOMIC logo are registered trademarks or trademarks of RIBOMIC Inc. in various jurisdictions.

Contacts for inquiries or additional information:

RIBOMIC Inc.

ir.inquiry@ribomic.com